Interim Analysis of DD3: A Phase IB/II Trial of Dose-Deescalated 3-Fraction SBRT for Centrally Located Lung Cancer
Description
CONCLUSION: Interim analysis of the DD3 trial suggests that for patients with central but not ultra-central lung tumors, an SBRT regimen of 45 Gy in 3 fractions warrants continued trial accrual and follow-up given no grade ≥3 toxicities or local
